Table 1.
Patient characteristics for uterine leiomyosarcoma (uLMS), uterine leiomyoma (uLM), and normal myometrium cases (uM)
| Uterine leiomyosarcomas (uLMS) n=53 | Uterine leiomyomas (uLM) n=53 | Uterine control myometrium (uM) n=53 | p-value | |
|---|---|---|---|---|
| Median age at therapy, years (IQR); min–max | 51.00 (8.00); 44.00–70.00 | n/a | ||
| Menopausal status, n (%) | n/a | |||
| Pre– | 30 (56.61%) | |||
| Post | 23 (43.39%) | |||
| FIGO stage, n (%) | n/a | n/a | n/a | |
| I | 27 (50.95%) | |||
| II | 5 (9.43%) | |||
| III | 12 (22.64%) | |||
| IV | 9 (16.98%) | |||
| Grade, n (%) | n/a | n/a | n/a | |
| 1 | 6 (11.32%) | |||
| 2 | 10 (18.87%) | |||
| 3 | 37 (68.81%) | |||
| Median primary tumor size, cm (IQR); min–max | 5.00 (7.00); 2.00–15.00 | 6.00 (2.00); 3.00–13.00 | n/a | 0.733 |
| Mitotic index, no of mitoses per 1 high power field, n (%) | n/a | n/a | n/a | |
| ≤50 | 38 (71.70%) | |||
| >50 | 15 (28.30%) | |||
| Adjuvant treatment, n (%) | n/a | n/a | n/a | |
| None | 21 (39.63%) | |||
| Radiotherapy (RTH) | 5 (9.43%) | |||
| Chemotherapy (CHT) | 22 (41.51%) | |||
| Combination of RTH and CHT | 5 (9.43%) | |||
| Median age of first menstrual period, years (IQR); min–max | 12.00 (2.00); 9.00–15.00 | 12.00 (2.00); 10.00–15.00 | 13.00 (1.00); 10.00–15.00 | p=0.009* |
| Median age of menopause, years (IQR); min–max (n=23) | 54.00 (2.00); 49.00–55.00 | 52.00 (4.00); 48.00–55.00 | 52.00 (1.00); 50.00–54.00 | p=0.061 |
| Median duration of menstrual cycle, days (IQR); min–max | 28.00 (2.00); 24.00–32.00 | 28.00 (1.00) 25.00–34.00 | 28.00 (0.00) 26.00–31.00 | p=0.408 |
| Median duration of menstruation, days (IQR), min–max | 4.00 (1.00); 3.00–7.00 | 4.00 (1.00); 3.00–7.00 | 4.00 (1.00); 3.00–6.00 | p=0.281 |
| Menstrual cycles, n (%) | p=0.164 | |||
| Regular | 36 (67.92%) | 32 (60.38%) | 42 (79.25%) | |
| Irregular | 17 (32.08%) | 21 (39.62%) | 11 (20.75%) | |
| Menstrual cycles, n (%) | p=0.510 | |||
| Painful | 13 (24.53%) | 15 (28.31%) | 9 (16.98%) | |
| Painless | 40 (75.47%) | 38 (71.69%) | 44 (83.08%) | |
| Type of menstrual bleeding, n (%) | p=0.038* | |||
| Scant | 4 (7.55%) | 2 (3.77%) | 4 (7.55%) | |
| Normal | 37 (69.81%) | 36 (67.92%) | 46 (86.79%) | |
| Heavy | 12 (22.64%) | 15 (28.31%) | 3 (5.66%) | |
| Parity, n (%) | p=0.403 | |||
| Nullipara | 5 (9.43%) | 3 (5.66%) | 2 (3.77%) | |
| Primipara | 4 (7.55%) | 9 (16.98%) | 5 (9.43%) | |
| Multipara | 44 (83.02%) | 41 (77.36%) | 46 (86.80%) |
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics classification of uLMS; IQR, interquartile range.